Similar articles

• [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].

  Giachino G, Giacchino F, Jeantet A, Del Piano A, Garetto A, Pellerey M, Piccoli G. Giachino G, et al. Minerva Med. 1985 Mar 10;76(9-10):407-14. Minerva Med. 1985. PMID: 2984605 Italian. No abstract available.
• [The course of osteodystrophy in patients with chronic kidney failure on hemodialysis].

  Zemchenko AIu, Shostka GD. Zemchenko AIu, et al. Urol Nefrol (Mosk). 1993 Nov-Dec;(6):51-4. Urol Nefrol (Mosk). 1993. PMID: 8160326 Review. Russian. No abstract available.
• Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.

  Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Dogan E, et al. Ren Fail. 2008;30(4):407-10. doi: 10.1080/08860220801964210. Ren Fail. 2008. PMID: 18569914 Clinical Trial.
• [Bone disease in patients with chronic renal failure and during long-term hemodialysis].

  Flury W. Flury W. Ther Umsch. 1972 Sep;29(9):554-9. Ther Umsch. 1972. PMID: 4628712 German. No abstract available.
• Renal bone disease--what is it and why does it happen?

  Feest TG, Ward MK, Ellis HA, Conceicao S, Pierides AM, Aird E, Simpson W, Cook DB, Kerr DN. Feest TG, et al. Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:19s-23s. doi: 10.1111/j.1365-2265.1977.tb03357.x. Clin Endocrinol (Oxf). 1977. PMID: 342144 Review. No abstract available.